Charles G Drake

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc Phenotypic and functional properties of Helios+ regulatory T cells
    Daniel J Zabransky
    Department of Oncology, Johns Hopkins University, Baltimore, Maryland, United States of America
    PLoS ONE 7:e34547. 2012
  2. ncbi request reprint Combination immunotherapy approaches
    C G Drake
    Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Ann Oncol 23:viii41-6. 2012
  3. pmc Current status of immunological approaches for the treatment of prostate cancer
    Charles G Drake
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Curr Opin Urol 22:197-202. 2012
  4. pmc Update on prostate cancer vaccines
    Charles G Drake
    Johns Hopkins Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    Cancer J 17:294-9. 2011
  5. pmc Update: immunological strategies for prostate cancer
    Charles G Drake
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB1 410, Baltimore, MD, 21231, USA
    Curr Urol Rep 11:202-7. 2010
  6. pmc Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen
    Charles G Drake
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Cancer Cell 7:239-49. 2005
  7. doi request reprint Immunotherapy for prostate cancer: an emerging treatment modality
    Charles G Drake
    Departments of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, 1650 Orleans Street CRB I 410, Baltimore, MD 21231, USA
    Urol Clin North Am 37:121-9, Table of Contents. 2010
  8. pmc Prostate cancer as a model for tumour immunotherapy
    Charles G Drake
    Johns Hopkins Kimmel Cancer Center, 1650 Orleans Street CRB 410, Baltimore, Maryland 21231, USA
    Nat Rev Immunol 10:580-93. 2010
  9. ncbi request reprint Basic overview of current immunotherapy approaches in urologic malignancy
    Charles G Drake
    Oncology, Immunology, and Urology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA
    Urol Oncol 24:413-8. 2006
  10. pmc Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
    Satoshi Wada
    Department of Oncology, Johns Hopkins University, School of Medicine, Baltimore, Maryland 21231, USA
    J Transl Med 11:89. 2013

Detail Information

Publications64

  1. pmc Phenotypic and functional properties of Helios+ regulatory T cells
    Daniel J Zabransky
    Department of Oncology, Johns Hopkins University, Baltimore, Maryland, United States of America
    PLoS ONE 7:e34547. 2012
    ..Taken together, these data show that Helios(+) Treg represent a functional subset with associated CD103 and GITR expression...
  2. ncbi request reprint Combination immunotherapy approaches
    C G Drake
    Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Ann Oncol 23:viii41-6. 2012
    ..Taken together, the available data provide a strong rationale for initiating combination clinical trials, but lend a note of caution in that issues of dosing and timing likely require careful exploration in a phase II setting...
  3. pmc Current status of immunological approaches for the treatment of prostate cancer
    Charles G Drake
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Curr Opin Urol 22:197-202. 2012
    ....
  4. pmc Update on prostate cancer vaccines
    Charles G Drake
    Johns Hopkins Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    Cancer J 17:294-9. 2011
    ..clinicaltrials.gov...
  5. pmc Update: immunological strategies for prostate cancer
    Charles G Drake
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB1 410, Baltimore, MD, 21231, USA
    Curr Urol Rep 11:202-7. 2010
    ..Enthusiasm for prostate cancer immunotherapy is founded upon its potential to mediate targeted, specific, tumor cell destruction without significant systemic toxicity; however, this has yet to be fully realized in the clinical arena...
  6. pmc Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen
    Charles G Drake
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Cancer Cell 7:239-49. 2005
    ..These results suggest that immunotherapy for prostate cancer may be most efficacious when administered after androgen ablation...
  7. doi request reprint Immunotherapy for prostate cancer: an emerging treatment modality
    Charles G Drake
    Departments of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, 1650 Orleans Street CRB I 410, Baltimore, MD 21231, USA
    Urol Clin North Am 37:121-9, Table of Contents. 2010
    ....
  8. pmc Prostate cancer as a model for tumour immunotherapy
    Charles G Drake
    Johns Hopkins Kimmel Cancer Center, 1650 Orleans Street CRB 410, Baltimore, Maryland 21231, USA
    Nat Rev Immunol 10:580-93. 2010
    ..Although this Review focuses on immunotherapy for prostate cancer, the principles discussed are applicable to many tumour types, and the approaches discussed are highlighted in that context...
  9. ncbi request reprint Basic overview of current immunotherapy approaches in urologic malignancy
    Charles G Drake
    Oncology, Immunology, and Urology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA
    Urol Oncol 24:413-8. 2006
    ..Various compensatory mechanisms which serve to down-regulate an antitumor response are also examined...
  10. pmc Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
    Satoshi Wada
    Department of Oncology, Johns Hopkins University, School of Medicine, Baltimore, Maryland 21231, USA
    J Transl Med 11:89. 2013
    ..As a single agent, ipilimumab is also being clinically evaluated in advanced (metastatic, castrate-resistant) prostate cancer and two randomized, placebo-controlled Phase III studies have recently completed accrual...
  11. pmc Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model
    Satoshi Wada
    Department of Oncology, James Buchanan Brady Urological Institute, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Cancer Res 69:4309-18. 2009
    ..Taken together, these data clarify the dose, timing, and mechanism of action by which immunomodulatory cyclophosphamide can be translated to a clinical setting in a combinatorial cancer treatment strategy...
  12. pmc A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells
    Derese Getnet
    Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA
    Mol Immunol 47:1595-600. 2010
    ..Taken together, these data suggest that Helios may play an important role in regulatory T cell function and support the concept that Helios may be a novel target to manipulate Treg activity in a clinical setting...
  13. pmc Radiotherapy augments the immune response to prostate cancer in a time-dependent manner
    Timothy J Harris
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Prostate 68:1319-29. 2008
    ..To address this, we utilized a well-established, autochthonous murine model of prostate cancer to test whether RT could augment (or diminish) the CD4 T cell response to a tumor vaccine...
  14. pmc Tc17 CD8 T cells: functional plasticity and subset diversity
    Hung Rong Yen
    Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Immunol 183:7161-8. 2009
    ..Tc17 also accumulated to a greater extent than did Tc1 cells, suggesting that adoptive transfer of CD8 T cells cultured in Tc17 conditions may have therapeutic potential for diseases in which IFN-gamma-producing cells are desired...
  15. ncbi request reprint Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer model
    Satoshi Wada
    Department of Oncology, James Buchanan Brady Urological Institute, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
    Int J Radiat Oncol Biol Phys 87:769-76. 2013
    ..To optimize the combination of ionizing radiation and cellular immunotherapy using a preclinical autochthonous model of prostate cancer...
  16. pmc Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells
    Derese Getnet
    Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA
    J Immunol 182:4675-85. 2009
    ..Interestingly, this Treg skewing was a property of even early-stage tumors, suggesting Treg induction as an important tolerance mechanism during tumor development...
  17. pmc Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells
    Joseph F Grosso
    Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Immunol 182:6659-69. 2009
    ....
  18. pmc LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems
    Joseph F Grosso
    Sidney Kimmel Comprehensive Cancer Center and Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    J Clin Invest 117:3383-92. 2007
    ..Taken together, these data demonstrate a direct role for LAG-3 on CD8+ T cells and suggest that LAG-3 blockade may be a potential cancer treatment...
  19. pmc Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines
    Gang Zhou
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Blood 107:628-36. 2006
    ....
  20. pmc A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells
    Paul E Zarek
    Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Blood 111:251-9. 2008
    ..Overall, our findings demonstrate that extracellular adenosine stimulates the A(2A)R to promote long-term T-cell anergy and the generation of adaptive regulatory T cells...
  21. pmc Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody
    Evan J Lipson
    Department of Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
    Clin Cancer Res 19:462-8. 2013
    ..Here, we provide long-term follow-up on three patients from that trial who sustained objective tumor regressions off therapy, and test the hypothesis that reinduction therapy for late tumor recurrence can be effective...
  22. pmc Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model
    Tullia C Bruno
    Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Prostate 72:514-22. 2012
    ..This may occur via deletion of tumor-specific T cells, through acquisition of an anergic phenotype, or via active suppression mediated by another population of cells...
  23. pmc Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing
    Karen Sandell Sfanos
    Department of Urology, James Buchanan Brady Urological Institute, MD, USA
    Clin Cancer Res 14:3254-61. 2008
    ..Little is known about the phenotype of these cells, despite accumulating evidence suggesting a potential role for chronic inflammation in the etiology of prostate cancer...
  24. ncbi request reprint Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity
    Timothy J Harris
    Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA
    J Immunol 179:4313-7. 2007
    ..Thus, STAT3 is a candidate target for T(H)17-dependent autoimmune disease immunotherapy that could selectively inhibit pathogenic immune pathways...
  25. ncbi request reprint Role of LAG-3 in regulatory T cells
    Ching Tai Huang
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Immunity 21:503-13. 2004
    ..We propose that LAG-3 marks regulatory T cell populations and contributes to their suppressor activity...
  26. pmc Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+
    Karen S Sfanos
    Department of Pathology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland 21231, USA
    Prostate 69:1694-703. 2009
    ....
  27. pmc Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
    Suzanne L Topalian
    Department of Surgery, Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
    N Engl J Med 366:2443-54. 2012
    ..Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks PD-1...
  28. pmc Strain-specific induction of experimental autoimmune prostatitis (EAP) in mice
    Christopher M Jackson
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Prostate 73:651-6. 2013
    ..Although several induced and spontaneous murine models of prostatitis have been explored, the role of genetic background on induction has not been well-defined...
  29. pmc Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells
    Fan Pan
    Immunology and Hematopoiesis Division, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Science 325:1142-6. 2009
    ..Silencing of Eos in Tregs abrogates their ability to suppress immune responses and endows them with partial effector function, thus demonstrating the critical role that Eos plays in Treg programming...
  30. pmc Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer
    Daniel J Zabransky
    Johns Hopkins Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, USA
    Prostate 72:487-98. 2012
    ....
  31. pmc Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas
    Jing Zeng
    Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins Medical Institutes, Baltimore, Maryland, USA
    Int J Radiat Oncol Biol Phys 86:343-9. 2013
    ..We tested the combination of anti-PD-1 immunotherapy with stereotactic radiosurgery in a mouse orthotopic GBM model...
  32. ncbi request reprint CD4+ T cells pass through an effector phase during the process of in vivo tolerance induction
    Ching Tai Huang
    Oncology Center and Division of Comparative Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    J Immunol 170:3945-53. 2003
    ..They also suggest that autoimmune pathology can result during the natural process of tolerance induction rather than requiring that tolerance be broken...
  33. pmc Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
    Julie R Brahmer
    Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA
    N Engl J Med 366:2455-65. 2012
    ..Blockade of interactions between PD-1 and PD-L1 enhances immune function in vitro and mediates antitumor activity in preclinical models...
  34. pmc Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells
    Monica V Goldberg
    Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA
    Blood 110:186-92. 2007
    ..These findings demonstrate that, in addition to modulating effector functions in the periphery, B7-H1:PD-1 interactions regulate early T-cell-fate decisions...
  35. pmc Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence
    Paul J Dluzniewski
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD 21205, USA
    Cancer Epidemiol Biomarkers Prev 21:1774-82. 2012
    ....
  36. pmc Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy
    Emmanuel S Antonarakis
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Curr Opin Oncol 24:258-65. 2012
    ..In this article, we will summarize recent clinical data on several additional immune-directed strategies, some of which have now entered phase 3 trials...
  37. pmc Current status of immunological therapies for prostate cancer
    Emmanuel S Antonarakis
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231, USA
    Curr Opin Urol 20:241-6. 2010
    ..This review will discuss the most promising immune-directed strategies in development for prostate cancer, outlining interventions that mitigate tumor-induced tolerance and highlighting several combination immunotherapy approaches...
  38. ncbi request reprint Current immunotherapeutic strategies in prostate cancer
    Joseph F Grosso
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, 1650 Orleans Street, CRB 452, Baltimore, MD 21231, USA
    Surg Oncol Clin N Am 16:861-71, x. 2007
    ..Most likely, successful immunotherapy will eventually require either the combination of multiple immunologic approaches or the combination of immunologic approaches with conventional therapy...
  39. pmc STAT3 signaling in CD4+ T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model
    Vedran Radojcic
    Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Immunol 184:764-74. 2010
    ....
  40. doi request reprint Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates
    Julie R Brahmer
    Johns Hopkins University School of Medicine, and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
    J Clin Oncol 28:3167-75. 2010
    ..This phase I study sought to determine the safety and tolerability of anti-PD-1 blockade in patients with treatment-refractory solid tumors and to preliminarily assess antitumor activity, pharmacodynamics, and immunologic correlates...
  41. pmc Intra-individual variation in serum C-reactive protein over 4 years: an implication for epidemiologic studies
    Elizabeth A Platz
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Rm E6132, Baltimore, MD 21205, USA
    Cancer Causes Control 21:847-51. 2010
    ..The authors estimated the size of this source of variability and consequent attenuation of the relative risk (RR)...
  42. pmc Cyclophosphamide unmasks an antimetastatic effect of local tumor cryoablation
    Moshe Yair Levy
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Pharmacol Exp Ther 330:596-601. 2009
    ..The combination of tumor cryoablation and Cy induces potent, systemic antitumor immunity in animals with established metastatic disease...
  43. pmc Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model
    Zineb Belcaid
    Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
    PLoS ONE 9:e101764. 2014
    ..Here, we evaluate a combination immunotherapy regimen involving 4-1BB activation, CTLA-4 blockade, and focal radiation therapy in an immune-competent intracranial GBM model...
  44. pmc Bacteriolytic therapy can generate a potent immune response against experimental tumors
    Nishant Agrawal
    Howard Hughes Medical Institute, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Proc Natl Acad Sci U S A 101:15172-7. 2004
    ..Similar effects were observed in rabbits with intrahepatic tumors. It was particularly notable that the induced immune response, when combined with the bacteriolytic effects of C. novyi-NT, could eradicate large established tumors...
  45. pmc Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma
    Sofia Lyford-Pike
    Department of Otolaryngology Head and Neck Surgery, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
    Cancer Res 73:1733-41. 2013
    ....
  46. pmc Resolution of infection promotes a state of dormancy and long survival of CD4 memory T cells
    Sarat K Dalai
    Department of Pathology, Johns Hopkins University, Baltimore, MD 21205, USA
    Immunol Cell Biol 89:870-81. 2011
    ..We propose that quiescence might be a mechanism necessary to regulate long-term survival of CD4 memory T cells and to prevent cross-reactivity to self, hence autoimmunity...
  47. pmc Inflammation in prostate carcinogenesis
    Angelo M De Marzo
    Johns Hopkins University School of Medicine, Department of Pathology, Baltimore, MD, USA
    Nat Rev Cancer 7:256-69. 2007
    ....
  48. pmc Potential role of decoy B7-H4 in the pathogenesis of rheumatoid arthritis: a mouse model informed by clinical data
    Takeshi Azuma
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    PLoS Med 6:e1000166. 2009
    ..Here we sought to investigate whether B7-H4, a cell surface inhibitory molecule of the B7-CD28 signaling pathway, may play a role in the pathogenesis of RA...
  49. pmc Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II
    Ming Hsi Wang
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe Street, Baltimore, MD 21205, USA
    Prostate 69:874-85. 2009
    ..Chronic intra-prostatic inflammation and obesity are thought to influence prostate carcinogenesis. Thus, variants in genes in these pathways could be associated with prostate cancer risk...
  50. doi request reprint Immunotherapy for metastatic prostate cancer
    Charles G Drake
    Department of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA
    Urol Oncol 26:438-44. 2008
    ..The relative advantages and disadvantages of current approaches will be noted, and ongoing clinical trials will be highlighted...
  51. doi request reprint LAG-3 in Cancer Immunotherapy
    Monica V Goldberg
    Johns Hopkins Kimmel Cancer Center, 1650 Orleans Street CRB 423, Baltimore, MD 21231, USA
    Curr Top Microbiol Immunol 344:269-78. 2011
    ..In this review, we will first discuss the basic structural and functional biology of LAG-3, followed by a review of preclinical and clinical data pertinent to a role for LAG-3 in cancer immunotherapy...
  52. pmc Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia
    Florencia McAllister
    Department of Oncology, Johns Hopkins University, Baltimore, MD 21205, USA Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
    Cancer Cell 25:621-37. 2014
    ..Together, these studies suggest that a hematopoietic-to-epithelial IL-17 signaling axis is a potent and requisite driver of PanIN formation. ..
  53. pmc Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
    Charles G Drake
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Baltimore, MD 21231, USA
    Nat Rev Clin Oncol 11:24-37. 2014
    ..In addition to being part of the current treatment armamentarium for metastatic melanoma, immune checkpoint blockade is currently undergoing phase III testing in several cancer types. ..
  54. pmc Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
    Suzanne L Topalian
    Department of Surgery, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
    Curr Opin Immunol 24:207-12. 2012
    ..Encouraging early clinical results using blocking agents against components of the PD-1 pathway have validated its importance as a target for cancer immunotherapy...
  55. pmc Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma
    Evan J Lipson
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Clin Cancer Res 17:6958-62. 2011
    ..Here, we review the mechanism of action, preclinical data, and multiple clinical trials that led to FDA approval of ipilimumab for metastatic melanoma...
  56. ncbi request reprint Epithelial architectural destruction is necessary for bone marrow derived cell contribution to regenerating prostate epithelium
    Ganesh S Palapattu
    Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    J Urol 176:813-8. 2006
    ....
  57. pmc Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells
    Ivan V Litvinov
    Chemical Therapeutics Program, Division of Immunology and Hematopoiesis, The Sidney Kimmel Comprehensive Cancer Center, Department of Pathology, and The Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Proc Natl Acad Sci U S A 103:15085-90. 2006
    ..Thus, AS prostate cancer cells do not express AR protein during mitosis, either in vitro or in vivo, consistent with AR functioning as a licensing factor for DNA replication in AS prostate cancer cells...
  58. ncbi request reprint A draft map of the human proteome
    Min Sik Kim
    1 McKusick Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA 2 Department of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Nature 509:575-81. 2014
    ..humanproteomemap.org) will complement available human genome and transcriptome data to accelerate biomedical research in health and disease. ..
  59. pmc Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy
    Christopher J Nirschl
    Authors Affiliation Departments of Oncology, Immunology, and Urology, Johns Hopkins Sidney Kimmel Comprehensives Cancer Center, Baltimore, Maryland
    Clin Cancer Res 19:4917-24. 2013
    ..Here, we review current data regarding immune checkpoint molecule signaling and coexpression, both in cancer and infectious disease, as well as the results of preclinical and clinical manipulations of checkpoint proteins...
  60. ncbi request reprint Tumor immunology--towards a paradigm of reciprocal research
    Charles G Drake
    Johns Hopkins Department of Medical Oncology, Baltimore, MD 21231, USA
    Semin Cancer Biol 12:73-80. 2002
    ..The results of early clinical trials illustrate these points and underscore the critical importance of an interactive dialog between laboratory and clinical research efforts...
  61. ncbi request reprint Cutting Edge: TCR-induced NAB2 enhances T cell function by coactivating IL-2 transcription
    Samuel Collins
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Immunol 177:8301-5. 2006
    ..Indeed, chromatin immunoprecipitation analysis reveals that NAB2 is recruited to the Egr-1 binding site of the IL-2 promoter. Taken together, our findings identify NAB2 as a novel coactivator of T cell function...
  62. pmc Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function
    Amy D H Doody
    Center for Immunotherapy of Cancer and Infectious Diseases, University of Connecticut Health Center, Farmington, CT 06030, USA
    J Immunol 172:6087-92. 2004
    ..Taken together, these data suggest that gp96 is an inflammatory mediator that selectively primes CD8 cell effector function...
  63. ncbi request reprint B and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly Induced in anergic CD4+ T cells
    Michelle A Hurchla
    Department of Pathology, Center for Immunology, Washington University School of Medicine, St Louis, MO 63110, USA
    J Immunol 174:3377-85. 2005
    ..These results clarify discrepancies regarding BTLA expression, suggest that structural and expression polymorphisms be considered when analyzing BTLA in various murine backgrounds, and indicate a possible role in anergic CD4+ T cells...
  64. ncbi request reprint Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy
    Evan T Keller
    Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA
    Cancer Res 67:9613-5. 2007

Research Grants4

  1. Regulation of the Immune Response to Prostate Cancer
    Charles Drake; Fiscal Year: 2007
    ..Finally, the research and training program outlined in this proposal makes full use of the collaborative and educational opportunities offered by the Johns Hopkins Oncology Center, where this work will be performed. ..
  2. Analysis of Lag-3 in Regulatory T Cell Function and Immune Supression
    Charles Drake; Fiscal Year: 2009
    ..The overall goal of these studies is to understand how LAG-3 works, and then to use this information to target LAG-3 in an effort to improve immune treatments for cancer patients. ..
  3. Analysis of Lag-3 in Regulatory T Cell Function and Immune Supression
    Charles G Drake; Fiscal Year: 2010
    ..The overall goal of these studies is to understand how LAG-3 works, and then to use this information to target LAG-3 in an effort to improve immune treatments for cancer patients. ..